Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Basic science of HER-2/neu: a review.

Hung MC, Lau YK.

Semin Oncol. 1999 Aug;26(4 Suppl 12):51-9. Review.

PMID:
10482194
2.

HER-2/neu-targeting gene therapy--a review.

Hung MC, Matin A, Zhang Y, Xing X, Sorgi F, Huang L, Yu D.

Gene. 1995 Jun 14;159(1):65-71. Review.

PMID:
7607574
3.

The role of the HER-2/neu oncogene in gynecologic cancers.

Cirisano FD, Karlan BY.

J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105. Review.

PMID:
8796816
4.

HER-2/neu signal transduction in human breast and ovarian cancer.

Reese DM, Slamon DJ.

Stem Cells. 1997;15(1):1-8. Review.

5.

HER2 overexpression and cancer targeting.

Wang SC, Hung MC.

Semin Oncol. 2001 Oct;28(5 Suppl 16):115-24. Review.

PMID:
11706403
6.

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy.

Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, Papamichail M.

Cancer Immunol Immunother. 2004 Mar;53(3):166-75. Epub 2003 Dec 18. Review.

PMID:
14685781
7.

Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.

Stancovski I, Peles E, Ben Levy R, Lemprecht R, Kelman Z, Goldman-Michael R, Hurwitz E, Bacus S, Sela M, Yarden Y.

J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):95-103. Review.

PMID:
1356018
8.

Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer.

Sahin AA.

Adv Anat Pathol. 2000 May;7(3):158-66. Review.

PMID:
10809222
9.

Cell growth regulation in epithelial ovarian cancer.

Bast RC Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A.

Cancer. 1993 Feb 15;71(4 Suppl):1597-601. Review.

10.

Targeted therapy in breast cancer: the HER-2/neu gene and protein.

Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN.

Mol Cell Proteomics. 2004 Apr;3(4):379-98. Epub 2004 Feb 3. Review.

12.

Biological and clinical significance of HER2 overexpression in breast cancer.

Kurebayashi J.

Breast Cancer. 2001;8(1):45-51. Review.

PMID:
11180765
13.

Breast cancer in the 21st century: neu opportunities and neu challenges.

Schnitt SJ.

Mod Pathol. 2001 Mar;14(3):213-8. Review.

14.

New insights into anti-HER-2 receptor monoclonal antibody research.

Kumar R, Mandal M, Vadlamudi R.

Semin Oncol. 2000 Dec;27(6 Suppl 11):84-91; discussion 92-100. Review.

PMID:
11236033
15.

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Review.

PMID:
11916237
16.

Role of HER2/neu in tumor progression and therapy.

Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E.

Cell Mol Life Sci. 2004 Dec;61(23):2965-78. Review.

PMID:
15583858
17.

Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer.

Menendez JA, Lupu R, Colomer R.

Drug News Perspect. 2005 Jul-Aug;18(6):375-85. Review.

PMID:
16247515
18.

Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior.

Bacus SS, Zelnick CR, Plowman G, Yarden Y.

Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S13-24. Review.

PMID:
7942609
19.

Perspectives on the future of cancer markers.

Bast RC Jr.

Clin Chem. 1993 Nov;39(11 Pt 2):2444-51. Review.

20.

The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology.

Brandt-Rauf PW, Pincus MR, Carney WP.

Crit Rev Oncog. 1994;5(2-3):313-29. Review.

PMID:
7849090

Supplemental Content

Support Center